Showing results (51-60 of 164) with videos related to
Sort By:
Pageof 17
Lung Cancer (Amsterdam, Netherlands)|March 26, 2020
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumabYuling Zhou, Wenjuan Jiang, Liang Zeng, et al.European Journal of Cancer (Oxford, England : 1990)|October 1, 2019
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastasesTao Jiang, Yongchang Zhang, Xuefei Li, et al.Oncotargets and Therapy|August 18, 2020
Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung CancerLiang Zeng, Yizhi Li, Qinqin Xu, et al.Cancer Chemotherapy and Pharmacology|July 25, 2018
Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutationDehua Liao, Dunwu Yao, Ni Liu, et al.Acta Psychologica|February 27, 2026
The effectiveness and feasibility of the new Forest parenting programme for Chinese children with attention-deficit/hyperactivity disorder and their familiesYongchang Zhang, Caiyan Liu, Bingxiao Li, et al.Cancer Medicine|November 17, 2022
Analysis of the efficacy and safety of immunotherapy in advanced thymoma patientsYue Hao, Gen Lin, Jing Xiang, et al.Optics Letters|July 1, 2025
Observation of an all-fiber Fano resonance combXiaofang Li, Ya'nan Wang, Meiqi Zhou, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 24, 2024
The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumorsHan Si, Xiaoshuang Fu, Yue Hao, et al.Frontiers in Pharmacology|May 28, 2020
Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer PatientsDehua Liao, Zhigang Liu, Yongchang Zhang, et al.Cell Death & Disease|December 21, 2022
Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancerHui Li, Yongchang Zhang, Yanjun Xu, et al.Pageof 17